JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber
Ken
K
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D017354:Point Mutation; D011087:Polycythemia Vera / Q000188:drug therapy / Q000235:genetics; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D013922:Thrombocytosis / Q000188:drug therapy / Q000235:genetics
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2